BioSpace News Archive

Olon Group and the Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering “Giulio Natta,” jointly announce an innovative public-private partnership agreement for a research project on the advanced study of polymorphism and the characterization of the solid state of the molecules of active ingredients.

Eurofins Environment Testing Northern California: Wastewater (EWW) and Eurofins Pandemic Prevention Services (EPPS) today launched a droplet digital PCR (ddPCR) assay for the quantitative analysis of SARS-CoV-2 Variant of Concern (VoC) XBB.1.5 in wastewater.

Immunovia will publish its full year 2022 results on February 23, 2023 at 8:30 am CET.

Covalon Technologies Ltd. announced its participation for the first time in the Conference for Neonatology in Las Vegas, Nevada from Wednesday, February 22 to Friday, February 24, 2023.

Antech Diagnostics, North America’s largest network of veterinary diagnostic reference laboratories, today announced that KeyScreen™ GI Parasite PCR will detect a new mutation for treatment-resistant canine hookworm by mid-April.

Lumitron Technologies, Inc., a company pioneering the development of a unique x-ray system, HyperVIEW™ EBCS, today announced its underlying accelerator technology has successfully generated electron beams that, for the first time, enable electron FLASH radiotherapy for a variety of next generation cancer treatments.

Medline announced it has entered a multi-year prime vendor partnership with Florida-based Synthase Collaborative, a partnership of four post-acute and home-based care organizations that provide not-for-profit hospice, palliative care, and other chronic Illness management community focused programs and services.

Maternova, Inc., accelerating advances in maternal and infant health through innovative, accessible solutions, and MedMira Inc. (TSXV: MIR), a developer and manufacturer of rapid diagnostics, today announced that the companies have entered into a multinational distribution agreement.

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced the results of its multinational Phase 2a clinical study (NCT 04596293) to evaluate the safety and efficacy of orally administered BBT-401 in subjects with active ulcerative colitis (UC).

AscletisPharma Inc. (HKEX: 1672, “Ascletis”) today presented positive data from Phase I clinical trial of ASC10, a broad-spectrum antiviral double prodrug, at Conference on Retroviruses and Opportunistic Infections (CROI) 2023 in Seattle, the U.S.